Evotec AG and Galapagos have entered a global collaboration focused on a novel target for fibrosis and other indications.   The collaboration concerns a small molecule program, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilized its in-house assay development and drug screening capabilities to ident...